CC
HZNP

Clearline Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Clearline Capital’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-35,000
Closed -$415K – 61
2017
Q2 		$415K Hold
35,000
– – 0.26% 40
2017
Q1 		$517K Hold
35,000
– – 0.24% 50
2016
Q4 		$566K Buy
+35,000
New +$635K 0.26% 41

Other funds holding HZNP

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Clearline Capital's HZNP Position: Q3 2017 in Review

Clearline Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2017, closing a stake of 35,000 shares — an estimated $415K sold.

Clearline Capital first reported a position in HZNP in Q4 2016 and held it in 3 quarters. The position peaked at $566K in Q4 2016. 181 funds tracked by Wall St. Rank hold HZNP as of Q3 2017.

  • Clearline Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Clearline Capital sold 35,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2017, an estimated $415K.
  • Clearline Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016 and held it in 3 quarters.
  • Clearline Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $566K in Q4 2016.
  • 181 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2017.

Based on Clearline Capital's 13F filing for Q3 2017, filed 14 Nov 2017.